By a News Reporter-Staff News Editor at Biotech Week -- In response to the company's recent growth, MolecularHealth announced the hiring of three new members of its U.S. sales team, filling the roles of regional vice president and senior account directors. Since the company's April launch of its cancer treatment decision support offering, TreatmentMAPô, MolecularHealth is seeing increased interest in and demand for its offering, which will be supported by its expanded sales team (see also MolecularHealth).
"As our business continues to grow, there are clear indicators that a larger sales presence in the U.S. is needed," said Chet Dye, senior vice president and chief development officer at MolecularHealth. "These new additions to the team reflect the great traction we are seeing since the recent launch of TreatmentMAP. With the demand for MolecularHealth's services increasing, we want to ensure our team is fully staffed with individuals highly-capable of delivering the best experiences to physicians and patients."
The three new additions to the sales team all come with strong backgrounds in pharmaceutical and diagnostics sales, each a former employee of Life Technologies. Matt Brunner, who will report to Dye, boards as regional vice president for the Western region, bringing over 15 years of sales experience, dedicated primarily to oncology. He is joined by Bruce Mrachek and Lee Stuart, who will serve as senior account directors for the Southwest and Southeast regions, respectively.
Dye continued, "The collective and individual experiences of Matt, Bruce and Lee in oncology, diagnostics and pharma bring additional value to our already-stellar sales team. This is a very exciting time at MolecularHealth and we are eager to make our offering more accessible to the West Coast and Southern regions." ABOUT MOLECULARHEALTH MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAPTM is a laboratory developed test (LDT) performed at MolecularHealth's CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world's leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass. Website: www.molecularhealth.com Blog: www.molecularhealth.com/blogTwitter: www.twitter.com/molecularhealthLinkedIn: www.linkedin.com/company/molecularhealthYouTube: www.youtube.com/user/MolecularHealthInc
Keywords for this news article include: Cancer, Oncology, MolecularHealth.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC